John C. Jacobs - Jan 23, 2024 Form 4 Insider Report for NOVAVAX INC (NVAX)

Role: President and CEO, Director
Signature: /s/ Mark J. Casey, Attorney-in-Fact
Stock symbol: NVAX
Transactions as of: Jan 23, 2024
Transactions value $: -$170,796
Form type: 4
Date filed: 1/25/2024, 05:00 PM
Previous filing: Jan 25, 2023
Next filing: Mar 26, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NVAX	Common Stock	Options Exercise		+83.2K			83.2K	Jan 23, 2024	Direct	F1
transaction	NVAX	Common Stock	Tax liability	-$171K	-40.1K	-48.19%	$4.26	43.1K	Jan 23, 2024	Direct

Showing 1 to 2 of 2 entries

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NVAX	Restricted Stock Units	Options Exercise	$0	-83.2K	-33.33%	$0.00	166K	Jan 23, 2024	Common Stock	83.2K		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.
F2	The RSUs subject to this grant under the Plan will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the January 23, 2023 grant date, in each case subject to continued employment through such vesting date.